Indication for CycloSam®

Metastatic Bone Cancers

Metastatic Bone Cancers

Metastatic bone cancers originate from other parts of the body but have metastasized to the bone. They are difficult and oftentimes impossible to treat. The most common metastatic bone cancers originate from cancers of the prostate, breast, and lung. Seven out of every 10 breast and prostate cancer patients will have bone metastases.

CycloSam® may or is proposed to be an effective tool for the treatment of metastatic bone cancers.

  • Single-agent for pain palliation (similar to Xofigo® population)

  • In combination with immunotherapy for potential systemic effect​

  • Sm-153 increases tumor antigenicity in animal models, suggesting potential synergy with immunotherapy